Oncology

Back to articles

Should Pharmacists Offer TDM Services for Oncology?

KEY POINT

A pharmacokinetic–pharmacodynamic model proved useful in predicting the white blood cell (WBC) time course—including nadir day and duration of leukopenia—in 44 patients with advanced breast cancer being treated with epirubicin (EPI; Ellence—Pfizer) and docetaxel (DTX; Taxotere—Aventis), a finding that could be applied clinically by pharmacists specializing in oncology and therapeutic drug monitoring (TDM).

SOURCES

Sandström M et al. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol. 2005;23:413–21.

Minami H. A point, a line, or an area? Which is the most important in the pharmacological analysis of cancer chemotherapy [editorial]? J Clin Oncol. 2005;23:405–6.